share_log

PhaseBio Pharmaceuticals (NASDAQ:PHAS) Trading Up 7%

PhaseBio Pharmaceuticals (NASDAQ:PHAS) Trading Up 7%

PhaseBio Pharmicals(纳斯达克股票代码:PHAS)交易上涨
Financial News Live ·  2022/11/17 00:42

PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS – Get Rating) shares were up 7% during trading on Wednesday . The stock traded as high as $0.11 and last traded at $0.10. Approximately 455,938 shares changed hands during trading, a decline of 46% from the average daily volume of 848,888 shares. The stock had previously closed at $0.10.

PhaseBio Pharmicals, Inc.(纳斯达克股票代码:PHAS — 获取评级)股价在周三的交易中上涨了7%。该股的交易价格高达0.11美元,最后一次交易价格为0.10美元。交易期间约有455,938股易手,较平均每日交易量848,888股下降了46%。该股此前收于0.10美元。

Analysts Set New Price Targets

分析师设定了新的价格目标

Several analysts have recently commented on PHAS shares. William Blair cut shares of PhaseBio Pharmaceuticals from an "outperform" rating to a "market perform" rating in a research note on Wednesday, September 28th. Cowen cut shares of PhaseBio Pharmaceuticals from an "outperform" rating to a "market perform" rating in a research note on Monday, October 24th. Stifel Nicolaus cut shares of PhaseBio Pharmaceuticals from a "buy" rating to a "hold" rating and reduced their price objective for the company from $15.00 to $1.00 in a research note on Wednesday, September 28th. Cowen cut shares of PhaseBio Pharmaceuticals to a "market perform" rating in a research note on Monday, October 24th. Finally, Needham & Company LLC cut shares of PhaseBio Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Wednesday, September 28th. Five research analysts have rated the stock with a hold rating, According to data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $4.50.

几位分析师最近对PHAS的股票发表了评论。威廉·布莱尔在9月28日星期三的一份研究报告中将PhaseBio Pharmicals的股票从 “跑赢大盘” 评级下调至 “市场表现” 评级。Cowen在10月24日星期一的一份研究报告中将PhaseBio Pharmicals的股票从 “跑赢大盘” 评级下调至 “市场表现” 评级。Stifel Nicolaus在9月28日星期三的一份研究报告中将PhaseBio Pharmicals的股票评级从 “买入” 评级下调至 “持有”,并将该公司的目标价格从15.00美元下调至1.00美元。Cowen在10月24日星期一的一份研究报告中将PhaseBio Pharmicals的股票下调至 “市场表现” 评级。最后,Needham & Company LLC在9月28日星期三的一份研究报告中将PhaseBio Pharmicals的股票评级从 “买入” 评级下调至 “持有”。五位研究分析师对该股进行了持有评级,根据MarketBeat的数据,该股的共识评级为 “持有”,共识目标价为4.50美元。

Get
获取
PhaseBio Pharmaceuticals
PhaseBio制药
alerts:
警报:

PhaseBio Pharmaceuticals Price Performance

PhaseBio 制药价格表现

The stock has a market capitalization of $5.17 million, a P/E ratio of -0.05 and a beta of 2.57. The business's 50 day simple moving average is $0.37 and its 200-day simple moving average is $0.75.

该股的市值为517万美元,市盈率为-0.05,beta值为2.57。该公司的50天简单移动平均线为0.37美元,其200天简单移动平均线为0.75美元。

Insiders Place Their Bets

业内人士下注

In other PhaseBio Pharmaceuticals news, major shareholder Enterprise Associates 13 L. New sold 1,784,109 shares of the stock in a transaction on Tuesday, October 25th. The shares were sold at an average price of $0.15, for a total value of $267,616.35. Following the sale, the insider now directly owns 4,857,525 shares in the company, valued at $728,628.75. The transaction was disclosed in a document filed with the SEC, which is available at
在PhaseBio Pharmicals的其他新闻中,主要股东Enterprise Associates 13 L. New在10月25日星期二的一笔交易中出售了该股1,784,109股。这些股票的平均价格为0.15美元,总价值为267,616.35美元。出售后,该内部人士现在直接拥有该公司的4,857,525股股票,价值728,628.75美元。该交易是在向美国证券交易委员会提交的文件中披露的,该文件可在
. Company insiders own 9.90% of the company's stock.
。公司内部人士拥有该公司9.90%的股份。

Institutional Investors Weigh In On PhaseBio Pharmaceuticals

机构投资者对 PhaseBio Pharmicals 表示关注

Several hedge funds have recently bought and sold shares of PHAS. MAI Capital Management acquired a new stake in PhaseBio Pharmaceuticals in the first quarter worth $1,872,000. Towercrest Capital Management acquired a new stake in shares of PhaseBio Pharmaceuticals during the first quarter worth $1,389,000. Resources Investment Advisors LLC. raised its holdings in shares of PhaseBio Pharmaceuticals by 959.8% during the third quarter. Resources Investment Advisors LLC. now owns 171,150 shares of the company's stock worth $30,000 after acquiring an additional 155,000 shares during the period. Jane Street Group LLC acquired a new stake in shares of PhaseBio Pharmaceuticals during the second quarter worth $68,000. Finally, Renaissance Technologies LLC acquired a new stake in shares of PhaseBio Pharmaceuticals during the first quarter worth $118,000. 49.02% of the stock is currently owned by institutional investors and hedge funds.

几家对冲基金最近买入和卖出了 PHAS 的股票。MAI资本管理公司在第一季度收购了PhaseBio Pharmicals的新股份,价值18.72万美元。Towercrest Capital Management在第一季度收购了PhaseBio Pharmicals的新股份,价值138.9万美元。资源投资顾问有限责任公司在第三季度将其持有的PhaseBio Pharmicals股票增加了959.8%。Resources Investment Advisors LLC. 在此期间又收购了15.5万股股票后,现在拥有该公司价值3万美元的171,150股股票。Jane Street Group LLC在第二季度收购了PhaseBio Pharmicals的新股份,价值68,000美元。最后,Renaissance Technologies LLC在第一季度收购了PhaseBio Pharmicals的新股份,价值11.8万美元。该股的49.02%目前由机构投资者和对冲基金持有。

PhaseBio Pharmaceuticals Company Profile

PhaseBio 制药公司简介

(Get Rating)

(获取评分)

PhaseBio Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapies for cardiovascular diseases. The firm's pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor, pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension, and PB6440, an oral agent for the treatment of resistant hypertension.

PhaseBio Pharmicals, Inc是一家处于临床阶段的生物制药公司,从事心血管疾病新疗法的开发和商业化。该公司的产品线包括:bentracimab(PB2452),一种用于抗血小板疗法的新型逆转药物 ticagrelor,pemziviptadil(PB1046),一种用于治疗肺动脉高压的每周一次的血管活性肠道肽受体激动剂,以及用于治疗耐药性高血压的口服药物 PB6440。

Recommended Stories

推荐故事

  • Get a free copy of the StockNews.com research report on PhaseBio Pharmaceuticals (PHAS)
  • Why Lowe's Is Up And Home Depot Down
  • The TJX Companies Could Break Out To New Highs
  • Gold Rush: Newmont Corp. is Starting to Sparkle
  • Four Healthcare Stocks To Watch This Week
  • Will It Be Smooth Sailing For Carnival After 56% One-Month Rally?
  • 免费获取 StockNews.com 关于 PhaseBio Pharmicals(PHAS)的研究报告的副本
  • 为什么 Lowe's 上涨而家得宝倒闭
  • TJX 公司可能会突破新高
  • 淘金热:纽蒙特公司开始大放异彩
  • 本周有四只值得关注的医疗保健股
  • 在56%的单月涨势之后,狂欢节会一帆风顺吗?

Receive News & Ratings for PhaseBio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PhaseBio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

接收PhaseBio制药日报的新闻和评级 -在下面输入您的电子邮件地址,通过Marketbeat.com的免费每日电子邮件时事通讯接收PhaseBio Pharmicals及相关公司的最新新闻和分析师评级的简明每日摘要。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发